In February, the FDA approved the first cancer therapy based on tumor-infiltrating lymphocytes (TILs). Although most advanced immunotherapies, such as CAR-Ts, have been largely aimed at blood-based ...
High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment. High tumor infiltrating lymphocytes (TILs) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback